Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: A case report

Clinical Colorectal Cancer

Volumn 6, Issue 7, 2007, Pages 529-531

  Heun, James ^a   Holen, Kyle ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

ABX EGF; Epidermal growth factor receptor; Hypersensitivity; Monoclonal antibodies

Indexed keywords

CAPECITABINE; CETUXIMAB; DEXAMETHASONE; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LORAZEPAM; OXALIPLATIN; PANITUMUMAB; PARACETAMOL;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLORECTAL CANCER; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMICOLECTOMY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; LOADING DRUG DOSE; MALE; METASTASIS; PHYSICAL EXAMINATION; TREATMENT CONTRAINDICATION;

EID: 34250372165     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2007.n.019     Document Type: Article

References (18)

1. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
2. Gibson TB, Ranganathan A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:29-31.
3. Hecht J, Mitchell E, Baranda J, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer expressing low (1-9%) or negative (<1%) levels of epidermal growth factor receptor (EGFr). J Clin Oncol 2006; 24(18 suppl):157s (Abstract #3547).
4. Berlin J, Neubauer M, Swanson P, et al. Panitumumab antitumor activity in patients (pts) with metastatic colorectal cancer (mCRC) expressing ≥ 10% epidermal growth factor receptor (EGFR). J Clin Oncol 2006; 24(18 suppl):158s (Abstract #3548).
5. Peeters M, Van Cutsem E, Siena S, et al. A phase 3, multicenter, randomized controlled trial (RCT) of panitumumab plus best supportive care (BSC) vs BSC alone in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: the 97th American Association for Cancer Research Meeting; April 1-5, 2006; Washington, DC. Abstract #CP-1.
6. Cohenuram M, Saif M. Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs 2007; 18:7-15.
7. Wainberg Z, Hecht JR. Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opin Biol Ther 2006; 6:1229-1235.
8. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984-990.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
10. Moore JM, Goldstein D, Hamm J, et al. Erlotinib improves survival when added to gemcitabine in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. Presented at: ASCO Gastrointestinal Cancers Symposium; January 27-29, 2005; Miami, FL. Abstract #77.
11. Shepherd FA, Rodrigues-Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
12. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
13. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
14. Saif MW, Cohenuram M. Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:118-124.
15. Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody for cancer therapy. Crit Rev Oncol Hematol 2001; 38:17-23.
16. Peeters M, Van Cutsem E, Hecht JR, et al. Efficacy and safety of panitumumab across five clinical studies in patients (pts) with metastatic colorectal cancer (mCRC). Presented at: ASCO Gastrointestinal Cancers Symposium; January 19-21, 2007; Orlando, FL. Abstract #336.
17. Hecht J, Posey J, Tchekmedyian S, et al. Panitumumab in combination with 5-fluorouracil, leucovorin, and irinotecan (IFL) or FOLFIRI for first-line treatment of metastatic colorectal cancer (mCRC). Presented at: ASCO Gastrointestinal Cancers Symposium; January 26-28, 2006; San Francisco, CA. Abstract #237.
18. PACCE: a randomized-open label, controlled, clinical trial of chemotherapy and bevacizumab with and without panitumumab in the first-line treatment of subjects with metastatic colorectal cancer. National Cancer Institute Web site. Available at: http://www.clinicaltrials.gov/ct/show/ NCT00115765. Accessed April 28, 2007.